Morgan Stanley Petros Pharmaceuticals, Inc. Transaction History

Morgan Stanley

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Oct 27, 2022	SELL	$0.68 - $1.49 $2,516 - $5,513	-3,700 Reduced 95.63%	169 $0
Q2 2022 Aug 15, 2022	SELL	$0.68 - $1.49 $2,516 - $5,513	-3,700 Reduced 95.63%	169 $0
Q1 2022 Oct 27, 2022	BUY	$1.07 - $3.36 $3,959 - $12,432	3,700 Added 2189.35%	3,869 $6,000
Q4 2021 Feb 14, 2022	BUY	$1.33 - $4.09 $4,921 - $15,133	3,700 Added 2189.35%	3,869 $13,000
Q3 2021 Nov 15, 2021	BUY	$1.82 - $3.2 $307 - $540	169 New	169 $0

Ticker PTPI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 20,708,000
Market Cap $6.42M
Description
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for th...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.